Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares.
- Barclays sees the company’s antibody-drug conjugate data in 2026 as a potential source of upside.
- MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.
- The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.
Barclays on Tuesday raised the firm’s price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.
Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company’s antibody-drug conjugate data in 2026 as a potential source of upside.
Pipeline Updates
MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.
Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.
Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.
The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.
How Did Stocktwits Users React?
On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.
MGNX stock has gained more than 50% over the past 12 months.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<